A Simple Imaging Guide for Endovascular Thrombectomy in Acute Ischemic Stroke: From Time Window to Perfusion Mismatch and Beyond

Wengui Yu* and Wei-Jian Jiang

1 Department of Neurology, University of California Irvine, Irvine, CA, United States, 2 New Era Stroke Care and Research Institute, The Rocket Force General Hospital, Beijing, China

Keywords: acute ischemic stroke (AIS), clinical-imaging mismatch, endovascular thrombectomy (EVT), ischemic penumbra, perfusion mismatch, symptomatic intracranial hemorrhage (sICH)

INTRODUCTION

Recent advances in medical and endovascular therapy have revolutionized stroke care. Intravenous thrombolysis (IVT) with tissue plasminogen activator (tPA) was shown to be effective for acute ischemic stroke (AIS) within 3 h of symptom onset in 1995 (1). Subsequent studies extended the time window to 4.5 h (2, 3). However, IV tPA was not very effective for stroke from large vessel occlusion (LVO) (4, 5).

Endovascular thrombectomy (EVT) was originally reported for patients with AIS from LVO in early 2000s (6–8). In 2013, 3 prospective, multi-center randomized controlled trials (RCTs), including the Interventional Management of Stroke (IMS) III (9), Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) (10), and Intra-Arterial vs. Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS EXP) (11), failed to show significant clinical benefit of EVT over standard medical therapy. No mandatory requirement for vascular imaging to screen for LVO (9, 11), nascent devices (9–11), and slow enrollment (10) may be the major limitations of these studies. However, a post hoc analysis of data from IMS III showed significant outcome benefit of EVT in the subgroup of patients with proven LVO (12).

In 2015, 5 RCTs independently demonstrated the safety and efficacy of EVT for AIS from LVO in the anterior circulation within 6–12 h of symptom onset (13–17). Three additional studies reported similar findings in 2016 (18–20). In early 2018, DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention (DAWN) and Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke (DEFUSE 3) trials extended the time window to 16–24 h after last known well (21, 22). These studies also showed that thrombectomy during the extended time window was not associated with significant higher risk of symptomatic intracranial hemorrhage (sICH) (21, 22).

In this review, we seek to appraise various imaging modalities used in the landmark studies and to propose a simple and efficient imaging guide for EVT in the real-world practice.

Imaging Modalities Used in Landmark RCTs

There were great variabilities in the use of imaging tools for patient selection in the recent RCTs. The key inclusion/exclusion criteria, main imaging modalities, and the thrombectomy devices used in the landmark studies are summarized in Table 1. Non-contrast CT and CTA were used to select patients with severe deficit and low infarct volume from LVO in most of the clinical trials.
(13, 15–20, 22). Advanced imaging tools, including CT perfusion (CTP), diffusion/perfusion MRI, and MRA, were used to identify patients with perfusion mismatch (i.e., small infarct and large ischemic penumbra) in EXTEND-IA, SWIFT PRIME, DEFUSE 3, and EXTEND-IA TNK trials (14, 17, 22, 23), or clinical-imaging mismatch (i.e., severe deficit and small infarct volume) in the DAWN trial (21). In ESCAPE trial, multiphase CTA was used to evaluate the extent of collateral circulation and patients with no or minimal collaterals were excluded from the study (15).

**CT and Alberta Stroke Program Early CT Score (ASPECTS)**

Non-contrast CT is widely available and can be performed within a few minutes of arrival. It is very sensitive in detecting hemorrhage (24, 25). During the first few hours of AIS, non-contrast CT is usually normal. A visible hypoattenuation on the CT is often irreversible (25). ASPECTS was developed to quantify early ischemic changes on non-contrast CT (26, 27). The scoring system divides the MCA territory into 10 zones on 2 axial CT slices at the levels of basal ganglion and the superior ganglionic margin (26). One point is subtracted for early ischemic change in each zone. A normal CT scan without any sign of ischemic change gets 10 points as shown in Figure 1. A score of 0 indicates diffuse ischemic changes in the entire MCA territory (26, 27).

ASPECTS can also be derived from CT angiographic (CTA) source image (28) or DWI image (16, 17, 29). CTA source image- and DWI-ASPECTS are more sensitive than non-contrast CT in the detection of early ischemic changes and prediction of final infarct volume (28, 29). The limitation of MRI is that it cannot be performed timely for acute stroke therapy at some medical centers.

Of note, ASPECTS score has a few limitations. First, it is limited to the anterior circulation (26). Second, it is based on anatomical structure with an unequal weighing of brain regions (30, 31). Its correlation with lesion volume is dependent on lesion location (31, 32). Last, it has poor sensitivity and inter-rater reliability for early ischemic changes (32, 33). However, the lower inter-rater reliability can be overcome by training (34).

ASPECTS score was found to be a strong predictor of clinical outcome after EVT (13, 16, 35). There was no difference in outcome between patients with ASPECTS 6–7 and 8–10 (16). A meta-analysis of the pooled data from the 5 landmark studies published in 2015 showed a clear benefit of thrombectomy in patients with ASPECT $\geq 6$ (35). When the treatment effect was analyzed for the 3 ASPECTS strata of 0–5, 6–8, and 9–10, there was a strong and consistent treatment effect for both ASPECTS 6–8 and 9–10 group with an adjusted odds ratio of 2.34 (95% CI: 1.68–3.26) and 2.66 (95% CI: 1.61–4.40), respectively (35). There was no clear benefit for the 121 patients with ASPECT 0–5. These findings appear to have validated the use of ASPECTS score 6–10 as surrogate marker of small infarct volume.

**CT Angiography (CTA) for Screening for LVO**

CTA of head and neck is a contrast study with high sensitivity and specificity for evaluation of cerebral vasculature and LVO (36). It also provides important information on collaterals, aortic arch, and cerebral ischemia (37–40). CTA may help interventionist to choose treatment strategy and reduce puncture-to-reperfusion time (39).

Decreased contrast enhancement on CTA source images is indicative of reduced cerebral blood volume (CBV) (34). CTA source images are more sensitive in predicting final infarct volume and outcome than non-contrast CT (28, 38, 40). Of note, slow contrast injection and quick image acquisition can lead to an overestimation of the infarct size (41).

Most landmark studies used CTA to select patients with severe deficit from LVO for EVT (13–22).

**CTA for Assessment of Collateral Circulation**

Collateral circulations are highly variable among patients (38, 42). They directly affect the size of ischemic penumbra and infarct progression after LVO (37, 42–44). CTA is the most commonly used imaging modality to assess collaterals (42). Multiphase CTA is better than conventional CTA because of the ability to examine collateral flow with time resolution (38). Dynamic CTA is able to evaluate time to retrograde filling and visualize distal branches of the cerebral artery trees. Digital subtraction angiography remains the gold standard given its triphasic evaluation of arterial, capillary, and venous circulation with high temporal and spatial resolution (38, 39). The degree of leptomeningeal collaterals can be semi-quantified by comparing the retrograde pial arterial filling to the contralateral hemisphere (37, 43). A major limitation of collateral assessment on CTA is that it is a single snap shot in time of contrast and may misdiagnose adequate collaterals as poor if the image is acquired early in the arterial phase (42, 43).

Optimal collateral circulation is associated with slower infarct progression and may allow for EVT outside of the traditional time window (43, 45). A good leptomeningeal collateral flow is associated with better outcome, lower rates of sICH and mortality after EVT (42, 44, 46, 47). A large infarct core and poor

---

**Abbreviations:** AIS, acute ischemic stroke; ASPECTS, Alberta Stroke Program Early CT Score; CT, computed tomography; EVT, endovascular thrombectomy; IQR, interquartile range; IVT, intravenous thrombolysis; OTT, onset to treatment; RCTs, randomized controlled trials; sICH, symptomatic intracranial hemorrhage; tPA, tissue plasminogen activator; DAWN, Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment with Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention; DEFUSE 3, Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke; ESCAPE, Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times; EXTEND-IA, Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Articular trial; IMS III, Interventional Management of Stroke III trial; MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; MR RESCUE, Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy; REVASCAT, Randomized Trial of Revascularization with Solitaire FR Device vs Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within 8h of Symptom Onset; SWIFT PRIME, Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment trial; SYNTHESIS EXP, Intra-Articular vs. Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS EXP) trial; THERAPY, The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke.
collaterals were shown to be strong predictors of poor functional outcome (46, 47). Based on these findings, the ESCAPE trial excluded patients with minimal or no pial collaterals (15).

Collateral assessment on CTA matched with the ASPECTS score on non-contrast CT. Minimal or no pial collaterals in >50% of MCA distribution was associated with an ASPECTS score of 5 or less (39). The DAWN and DEFUSE 3 trials demonstrated the benefit of late recanalization within 16–24 h using clinical-infarct mismatch profile indicative of good collaterals (21, 22).

Recent systemic review and meta-analysis have confirmed the favorable impact of good collateral status on functional outcome after EVT (44, 48, 49).

TABLE 1 | Landmark studies of EVT for AIS from LVO in the anterior circulation.

| Study                  | Patient (n) | Key inclusion criteria                                                                 | Key exclusion criteria                  | Main imaging modalities                  | EVT devices          |
|------------------------|-------------|----------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------|----------------------|
| MR CLEAN (13)          | 233         | Age ≥ 18, NIHSS ≥ 2, LVO, IVT < 4.5 h, EVT < 6 h                                        | BP > 185/110 mmHg, coagulopathy, active or recent hemorrhage | CT, CTA, CT perfusion (88%)              | Retrieval stent      |
| EXTEND-IA (14)         | 35          | Age ≥ 18, NIHSS ≥ 6, LVO, IVT < 4.5 h, ischemic core < 70 mL, mismatch volume ≥ 10 mL, EVT < 6 h | Intracranial hemorrhage, any terminal illness | CT, CTA, CT perfusion                   | Solitaire device     |
| ESCAPE (15)            | 165         | Age ≥ 18, NIHSS ≥ 5, LVO, IVT < 4.5 h, small infarct core, EVT < 12 h                  | ASPECTS 0–5, no or minimal collaterals  | CT, CTA                                  | Available thrombectomy device |
| SWIFT PRIME (16)       | 98          | Age 18–80, NIHSS 8–29, LVO, IVT < 4.5 h, small to moderate infarct core, EVT < 8 h     | Hemorrhage, tumor or vacuities on CT or MRI, > 1/3 MCA territory or 100 ml infarct, DWI-ASPECTS ≤ 5 | CT, CTA, CT perfusion | Solitaire stent retriever |
| REVASCAT (17)          | 103         | Age 18–80, NIHSS ≥ 6, LVO, IVT < 4.5 h, EVT < 6 h                                      | Large ischemic core (ASPECTS ≤ 7 on CT or 6 on DWI MRI) | CT, CTA, MRI                            | Solitaire stent retriever |
| THERAPY (18)           | 108         | Age 18–85, NIHSS ≥ 8, LVO, ≥ 8 mm clot length                                         | ≥ 1/3 MCA territory infarct, cervical ICA stenosis/occlusion | CT, CTA                                  | Penumbra             |
| THRACE (19)            | 414         | Age 18–80, NIHSS 10–25, LVO, IVT < 4 h, EVT < 8 h                                      | Cervical ICA stenosis/occlusion         | CT, CTA, or MRA/MRI                     | Stent retriever, Penumbra |
| PISTE (20)             | 65          | Age ≥ 18, NIHSS ≥ 6, LVO, IVT < 4.5 h, EVT < 6 h                                      | Contraindicated for IVT, > 1/3 MCA territory infarct, rapid improvement in neuro status, active or recent hemorrhage, Coagulopathy | CT, CTA                                  | Penumbra             |
| DAWN (21)              | 107         | Age ≥ 18, NIHSS ≥ 10, LVO, small infarct core (< 1/3 MCA territory), a mismatch between clinical deficit and infarct volume EVT 6–24 h | BP > 185/110 mmHg, coagulopathy, ASPECTS score < 6 on non-contrast CT | CT perfusion 75%, MR perfusion/diffusion 25% | Trevo retriever |
| DEFUSE 3 (22)          | 92          | Age 18–85, NIHSS ≥ 6, LVO, ischemic core < 70 mL, mismatch ratio > 1.8, mismatch volume ≥ 15 mL, or DWI volume < 25 mL EVT 6–16 h | BP > 185/110 mmHg, coagulopathy, ASPECTS score < 6 on non-contrast CT | CT perfusion 75%, MR perfusion/diffusion 25% | Trevo retriever |

FIGURE 1 | Alberta Stroke Program Early Computed Tomography Score (ASPECTS). The scoring system divides the MCA territory into 10 zones at ganglionic and supra-ganglionic levels: 6 for cortical regions (M1–M6), and 4 subcortical regions (C, caudate; L, lentiform; IC, internal capsule; and I, insular ribbon).

Magnetic Resonance Imaging (MRI) and Magnetic Resonance Angiography (MRA)

MRI/MRA can also be used to evaluate AIS and LVO. Diffusion weighted image (DWI) is highly sensitive and specific for the detection of early ischemic changes within the first 6 h of symptom onset (50–52). Early reversible ischemia has very mild depression in apparent diffusion coefficient (ADC) due to mild reduction in cerebral blood flow (CBF) (50, 51). Timely reperfusion therapy may reverse diffusion abnormalities (52). In the absence of reperfusion, diffusion abnormalities are often irreversible (52, 53). A good stroke MR protocol should include DWI, FLAIR, and SWI (33, 54).
MRA is a good option for assessment of LVO and collateral circulation (33, 55). Time-of-flight (TOF) and contrast-enhanced (CE) MRA provide good vascular images through the neck and the Circle of Willis (55). CE MRA is performed with a rapid, short repetition time gradient echo sequence following an IV bolus of gadolinium. It is minimally invasive and offers better diagnostic accuracy than TOF-MRA in localizing LVO (55).

MRI/MRA were used as imaging tools in a few landmark studies (16, 17, 19–22).

In SWIFT PRIME and REVASCAT, 17.4% and 5.3% of patients had MRI studies for patient screening (15, 16). The DAWN and DEFUSE 3 trials used more advanced imaging tools, including diffusion/perfusion MRI, for patient selection (21, 22).

Of note, the use of MRI/MRA for patient selection has some drawbacks. It takes time to screen the patients for metallic implants and to access the scanner (33, 54, 55). The images tend to be more susceptible to patient motion. In addition, it is more difficult to monitor unstable patients in the MRI suite (33, 54).

**CT Perfusion (CTP) and Diffusion/Perfusion MRI**

Acute LVO may lead to significant reduction of cerebral blood flow (CBF), resulting in a small irreversible infarct core and surrounding area of ischemic tissue that may be salvaged with prompt reperfusion (ischemic penumbra) (56, 57). Without reperfusion, the infarct core can expand and reach the size of the ischemic penumbra depending on duration of LVO and collaterals (56, 57).

CTP is a dynamic contrast-enhanced study developed for the analysis of the infarct core and ischemic penumbra per CBF; mean transition time (MTT) and cerebral blood volume (CBV) (58–62). The infarct core is defined as an area of brain tissue with more than 70% reduction in CBF compared to normal contralateral hemisphere and the ischemic penumbra is defined as an area with > 6 s of delayed arrival of contrast (39, 59–62). The ischemic penumbra is identified by a mismatch between CBF and CBV, whereas the infarct core has a matched decrease in both CBF and CBV (61–64). The mismatch between infarct core and penumbra is an indirect measurement of collateral blood flow (49).

The diffusion/perfusion MRI is very sensitive in the detection of infarct core and perfusion mismatch (51, 61, 65–70). MRI may predict clinical response to early reperfusion therapy (65–70). However, tissue at risk can be overestimated by perfusion-weighted imaging (71).

Both CTP and MR perfusion images can be obtained with high-speed CT and MR imaging systems within 10 min (22, 61). The data processing is similar. CTP or diffusion/perfusion MRI was used to assess infarct core and ischemic penumbra in EXTEND-IA, SWIFT PRIME, EXTEND IA-TNK, DAWN, and DEFUSE 3 (14, 16, 21–23).

CTP was performed in 66.8% of the patients in the MR CLEAN trial (13). It was shown that a large infarct core was associated with poor functional outcome. Both EXTEND-IA and SWIFT-PRIME used CTP to select patients with small infarct core (IQR 4–32 and 0–16 ml, respectively) for EVT (Table 1) (14, 16). Such strict selection criteria led to the highest rate of favorable outcome ever reported with EVT (60 and 71%, respectively) (14, 16). However, these studies may have excluded patients who could benefit from EVT (16, 64, 72, 73).

The DAWN trial evaluated the safety and efficacy of EVT for patients with LVO within 6–24 h of last known well (21). Approximate 60% of the patients had wake-up stroke. The key inclusion criteria were severe clinical deficit and a small infarct core on MRI or CTP. The rate of functional independence at 90 days was 49% after EVT as compared to 13% in the control group.

In DEFUSE 3 trial, CTP was performed in 73% of the patients and diffusion/perfusion MRI was done in the other 27% (22). Inclusion criteria includes an initial infarct volume < 70 ml, a ratio of ischemic penumbra to infarct core ≥ 1.8, and an absolute mismatch ≥ 15 ml. The study enrolled patients with perfusion mismatch for EVT within 6–16 h after last known well. The rate of functional independence at 90 days was significantly higher than control group (45 vs. 17%) (22).

Both DAWN and DEFUSE 3 trials demonstrated significant benefit of EVT within 16–24 h of last known well by selecting patients with clinical-imaging mismatch (i.e., severe deficit and small infarct core) per advanced imaging tools. The median NIHSS score with IQR was 17 (13–21) and 16 (10–20) while the median infarct core with IQR was 7.6 (2–18) and 9.4 (2.3–25.6) ml, respectively (Table 2) (21, 22). These results led to a paradigm shift from “time window” to “tissue window” per advanced perfusion imaging.

**TABLE 2 | Clinical-infarct volume mismatch as eligibility criteria for EVT in recent landmark studies.**

| Study            | Median NIHSS (IQR) | Median ASPECTS (IQR) | Median infarct core per advanced imaging-ml (IQR) | sICH (%) | Favorable outcome (%) |
|------------------|-------------------|----------------------|-----------------------------------------------|----------|----------------------|
| MR CLEAN (13)    | 17 (14–21)        | 9 (7–10)             | -                                              | 7.7      | 33                   |
| EXTEND-IA (14)   | 17 (13–20)        | NR                   | 12 (4–32)                                      | 0        | 71                   |
| ESCAPE (15)      | 16 (13–20)        | 9 (8–10)             | -                                              | 3.6      | 53                   |
| SWIFT PRIME (16) | 17 (13–20)        | 9 (8–10)             | 6 (0–16)                                       | 1.0      | 60                   |
| REVASCAT (17)    | 17 (14–20)        | 7 (6–9)              | -                                              | 1.9      | 44                   |
| THERAPY (18)     | 17 (14–21)        | 7.5 (6–9)            | -                                              | 9.3      | 38                   |
| THRACE (19)      | 18 (15–21)        | 5–10                 | -                                              | 2        | 53                   |
| PISTE (20)       | 18 (6–24)         | 5–10                 | -                                              | 0        | 51                   |
| DAWN (21)        | 17 (13–21)        | NR                   | 7.6 (2.0–18.0)                                 | 6        | 49                   |
| DEFUSE 3 (22)    | 16 (10–20)        | 8 (7–9)              | 9.4 (2.3–25.8)                                 | 7        | 45                   |

IQR, interquartile range; NR, not reported.

a Advanced imaging of perfusion CTP or diffusion/perfusion MRI was used to quantify infarct core and ischemic penumbra (14, 16, 21, 22).

b sICH was defined as intraparenchymal hematoma, subarachnoid hemorrhage, or intraventricular hemorrhage associated with a worsening of the NIHSS score by ≥ 4 points within 24 h (3).
Patient Selection per Perfusion Imaging and Beyond
Recent studies suggested that the selection criteria per advanced perfusion imaging in Dawn and DEFUSE 3 trials may have excluded a significant proportion of patients who could benefit from EVT. In a single center study of 79 patients comparing admission infarct core per CTP and final infarct on followup CT, Boned et al. showed that CTP overestimated infarct core for more than 10 mL in 38% of the patients (72). Therefore, CTP-based patient selection may deny treatment to patients who might benefit from reperfusion therapy. In a matched case-controlled study of patients with LVO on CTA and baseline ischemic core >50 mL on CTP, EVT was associated with significantly improved functional outcome at 90 days (73). In a study of prospectively collected data, 38% of the DAWN-eligible patients and 41% of DEFUSE 3 ineligible patients achieved functional independency at 90 days after EVT (74). In another retrospective study, 30% of DAWN and/or DEFUSE 3 ineligible patients achieved functional independence after off-label EVT (75). Two additional studies showed that EVT could benefit patients with large infarct core (DWI-ASPECTS ≤5 or DWI lesion >70 mL) (76, 77). EVT was also reported to be safe and effective for patients who met all DAWN trial criteria but were treated beyond 24 h of last known well (78).

Figure 2 showed a typical example of EVT for wake-up stroke from middle cerebral artery occlusion. CTP or diffusion/perfusion MRI may be unnecessary in clinical practice in appropriately selected patients (13, 15–20).

Major Complication of EVT: Symptomatic Intracranial Hemorrhage (sICH)
The periprocedural sICH is the most feared complication of EVT (13–22, 57). Early pathophysiological responses to sudden LVO are distal vasodilation to compensate for dramatic reduction in tissue perfusion and subsequent loss of vascular reactivity. Reperfusion leads to blood overflow into the dilated vasculature, resulting in hyperperfusion, cerebral edema, capillary leak, or hemorrhage (57, 79). Endothelial cell injury and impairment of the blood-brain barrier (BBB) are likely the underlying mechanism of ICH (79). The primary predictors of sICH are infarct volume (80), low CBV (70), and severely delayed CBF due to poor collaterals (81). Intensive management of high blood pressure may reduce the risk of reperfusion injury and sICH (82).

The rate of sICH from EVT ranged from 0 to 9.3% in the 10 RCTs (Table 2). That was comparable to the risk of sICH in the medical arms (13–22). Meta-analysis of data from the 5 landmark studies published in 2015 showed that the rate of sICH increased only slightly with delayed EVT (35). EVT within 16–24 h of last known well was not associated with significant higher rate of sICH (21, 22).

Perspectives: From Time Window to Perfusion Mismatch and Beyond
Advanced perfusion imaging used in the 4 landmark studies has helped demonstrating the best treatment effect of EVT (14, 16), and extending the treatment window up to 16–24 h of last known well (21, 22). However, the median infarct core was only 12,
6, 7.6, and 9.4 ml in EXTEND-IA, SWIFT PRIME, DAWN, and DEFUSE 3 trials, respectively, (Table 2) (14, 16, 21, 22), as compared to 49.7 ml in MR CLEAN (13, 83). Therefore, the best treatment effect in the studies using advance perfusion imaging is likely the results of strict selection of patients with small infarct core for EVT (14, 16, 21, 22). There are increasing evidence to suggest the limitations of advanced imaging modalities in the real-world practice.

First, in a recent systematic review and meta-analysis of individual patient data from all recent RCTs that compared EVT with standard medical therapy, perfusion mismatch was not associated with either functional independence or functional improvement (84). Patient should not be excluded from EVT within 6 h of stroke onset purely on the basis of a large estimated ischemic core.

Second, the use of perfusion imaging for patient selection may cause delay in reperfusion therapy (22, 55). In a meta-analysis of pooled data from the 5 RCTs published in 2015, earlier treatment with EVT was associated with lower degrees of disability (84). The more recent meta-analysis showed that 30-min delay in imaging-to-reperfusion time had a similar adverse effect on functional outcome as a 10-ml increase in ischemic core volume (85). In a recent cohort study, the use of advanced modality imaging was shown to delay EVT without improvement in clinical outcomes (86).

Third, the selection criteria per advanced perfusion imaging may exclude a significant proportion of eligible patients (16, 73–77). CTP and MRI diffusion/perfusion were shown to overestimate infarct core (71, 72). A number of recent studies demonstrated that thrombectomy may benefit DAWN and/or DEFUSE-3 ineligible patients (73–77).

Last, perfusion imaging capability is not readily available, in particular, in developing regions. A significant proportion of eligible patients world-wide would be deprived from the proven therapy if perfusion imaging criteria be strictly adhered to in clinical practice.

When designing clinical trials, it makes sense to use advanced imaging tools for patient selection in order to achieve the best treatment effect in small sample size studies. Since EVT has been independently proven effective by 10 RCTs (13–22), it is imperative to provide the therapy to all eligible patients in the fastest puncture-to-reperfusion time.

Of the 10 RCTs that independently demonstrated the powerful efficacy of EVT, 8 validated the use of ASPECTS score for the assessment of early infarct (13, 15, 17–20, 22). As shown in Table 2, clinical-imaging mismatch (i.e., high NIHSS and ASPECTS) is clearly a good indication for EVT in the real-world practice.

**Proposed Simple Imaging Guide for EVT**

The ideal imaging guide for decision-making for EVT should be widely available, quick to perform and interpret, and sensitive for the detection of early infarct, LVO and collaterals (13–22, 39).

NIHSS is a good surrogate marker for clinical deficit (87, 88) and ASPECTS has been validated for the assessment of early infarct in the anterior circulation (13, 15, 17–20, 22, 35). As shown in Table 1, all of the 10 recent RCTs used NIHSS scores as

---

**FIGURE 3** | Proposed simple imaging guide for endovascular thrombectomy.
eligibility criteria ($\geq 2$, $\geq 5$, $\geq 6$, $\geq 8$, $\geq 10$, $8-29$, and $10-25$) (13–22). From these studies, there are insufficient data to determine whether there is an overall net benefit from EVT in patients with NIHSS score 2–5 (13, 15, 89). A NIHSS score $\geq 6$ was the minimum used in 4 trials (14, 17, 20, 22), fulfilling the AHA’s Level of A evidence. The other 4 trials used higher NIHSS score ($\geq 8$) (16, 18, 19, 21). Meta-analysis of the pooled data from the 5 RCTs published in 2015 showed strong efficacy of thrombectomy in patients with ASPECTS $\geq 6$ (35). Therefore, NIHSS $\geq 6$ and ASPECTS $\geq 6$ from LVO are evidence-based cut-off values for timely decision-making for thrombectomy (90, 91).

Based on data from recent landmark studies, we propose the following simple and efficient imaging guide for decision-making for EVT (Figure 3). In patients with suspected acute stroke, non-contrast CT is performed to assess IV tPA eligibility and ASPECTS score. CTA is then performed to evaluate LVO and collaterals. In patients with significant clinical-imaging mismatch (NIHSS $\geq 6$ and ASPECTS $\geq 6$) from LVO, EVT should be considered immediately per AHA guidelines (90, 91). In patients without clinical-imaging mismatch (NIHSS $\geq 6$ and ASPECTS $\leq 5$), advanced perfusion imaging is recommended to identify salvageable ischemic penumbra. This simple and efficient imaging protocol may lead to EVT for most eligible patients in the fastest onset-to-reperfusion time. Two recent studies have shown the safety and effectiveness of simplified imaging protocol in patients with wake-up or late presenting stroke (89, 92).

Of note, ASPECTS has low inter-rater reliability, especially in early time window (32, 33, 93). For patients with a high ASPECTS and a LVO on CTA, the ASPECTS-based guideline is an easy and fast protocol to safeguard earliest treatment. In cases with low ASPECTS ($\leq 5$) or uncertain eligibility, a multimodal imaging study should be used to rescue patients with salvageable ischemia.

**CONCLUSION**

EVT is a proven therapy for appropriately selected patients with AIS from LVO up to 24 h of symptom onset (13–22). Although advanced perfusion imaging may better define infarct core and ischemic penumbra, they have a number of limitations for the real-world practice. A simple imaging protocol with non-contrast CT and CTA to identify clinical-imaging mismatch (NIHSS $\geq 6$ and ASPECTS $\geq 6$) from LVO may be the best guide for EVT in clinical practice. Advanced perfusion imaging is recommended in patients with large infarct core to identify additional candidates for the best possible care.

**AUTHOR CONTRIBUTIONS**

WY contributed to literature review, manuscript draft and final revision. W-JJ contributed to discussions of important intellectual contents and manuscript revision.

**REFERENCES**

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute hemisphere stroke. *N Engl J Med.* (1995) 333:1581–7. doi: 10.1056/NEJM1995121413332401

2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after ischemic stroke. *N Engl J Med.* (2008) 359:1317–29. doi: 10.1056/NEJMoa0804656

3. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. *Lancet.* (2010) 375:1695–703. doi: 10.1016/S0140-6736(10)60491-6

4. Bhatia R, Hill MD, Shobha N, Bal S, Kochar P, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. *Stroke.* (2010) 41:2254–8. doi: 10.1161/STROKEAHA.110.592355

5. Riedel CH, Zimmermann P, Jensen-Kondering U, Stingle J, Deuschl G, Jansen O, Riedel CH, et al. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. *Stroke.* (2011) 42:1775–7. doi: 10.1161/STROKEAHA.110.609693

6. Chopko BW, Kerber C, Wong W, Georgy B. Transcatheter snare removal of acute middle cerebral artery thromboembolism: technical case report. *Neurosurgery.* (2000) 46:1529–31. doi: 10.1093/neuros/46.5.1529

7. Mayer TE, Hamann GF, Brueckem JH. Treatment of basilar artery embolism with mechanical extraction device: necessity of flow reversal. *Stroke.* (2002) 33:2232–5. doi: 10.1161/01.STR.0000024524.71680.CS

8. Yu W, Binder D, Foster-Barber A, Malek R, Smith WS, Higashida RT. Endovascular embolectomy of acute basilar artery occlusion. *Neurology.* (2003) 61:1421–3. doi: 10.1212/01.wnl.0000103421

9. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous tPA versus tPA alone for stroke. *N Engl J Med.* (2013) 368:893–903. doi: 10.1056/NEJMoa1214300

10. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. *N Engl J Med.* (2013) 368:914–23. doi: 10.1056/NEJMoa1212793

11. Ciccone A, Valvassori L, Nichelli M, Sgoifo A, Ponzi M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. *N Engl J Med.* (2013) 368:904–13. doi: 10.1056/NEJMoa1213701

12. Demchuk AM, Goyal M, Yeatts SD, Carrozzella J, Foster LD, Qazi E, et al. for the IMS III Investigators. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. *Radiology.* (2014) 273:202–10. doi: 10.1148/radiol.14132649

13. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Vooi AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* (2015) 372:11–20. doi: 10.1056/NEJMoa1411587

14. Campbell BC, Mitchell PJ, Kleig MJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* (2015) 372:1009–18. doi: 10.1056/NEJMoa1414792

15. Goyal M, Demchuk AM, Monen BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* (2015) 372:1019–30. doi: 10.1056/NEJMoa1414905

16. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EL, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med.* (2015) 372:2285–95. doi: 10.1056/NEJMoa1415061

17. Jovin TG, Chamorro A, Cobo E, de Miguel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* (2015) 372:2296–60. doi: 10.1056/NEJMoa1503780

18. Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, et al. THERAPY Trial Investigators. Aspiration thrombectomy after intravenous t-PA versus intravenous alteplase alone. *Stroke.* (2016) 47:2331–8. doi: 10.1161/STROKEAHA.116.013372

19. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol.* (2016) 15:1138–47. doi: 10.1016/S1474-4422(16)30177-6
Yu and Jiang

A Simple Imaging Guide for Thrombectomy

20. Muir KW, Ford GA, Messow CM, Ford I, Murray A, Clifton A, et al. PISTE Investigators. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial. J Neurol Neurosurg Psychiatry. (2017) 88:38–44. doi: 10.1136/jnnp-2015-314113

21. Nonencht EA, Judah, AP Haussen, DC Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. (2018) 378:11–21. doi: 10.1056/NEJMoa1706442

22. Albers, GW, Marks, MP, Kemp, S. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. (2018) 378:708–18. doi: 10.1056/NEJMoa1713973

23. Campbell BC, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Ternecetapele versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. (2018) 378:1573–82. doi: 10.1056/NEJMoa1716405

24. von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. (1997) 205:327–33. doi: 10.1148/radiol.205.2.9356611

25. Dippel DW, Du Ry van Beest Holle M, van Kooten F, Koudstaal PJ. The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain. (2009) 132:2231–8. doi: 10.1093/brain/awp155

26. Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Orbieagle B, et al. Collateral flow predicts response to endovascular therapy for acute ischemic stroke. Stroke. (2011) 42:693–9. doi: 10.1161/STROKEAHA.110.595256

27. Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Orbieagle B, et al. Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke. Stroke. (2011) 42:2235–9. doi: 10.1161/STROKEAHA.110.604603

28. Bang OY, Goyal M, Liebeskind DS. Impact of time-to-perfusion on outcome in patients with poor collaterals. AJNR Am J Neuroradiol. (2015) 36:495–500. doi: 10.3174/ajnr.A4151

29. Bang OY, Goyal M, Liebeskind DS. Collateral circulation in ischemic stroke: assessment tools and therapeutic strategies. Stroke. (2015) 46:3302–9. doi: 10.1161/STROKEAHA.115.010508

30. Warach S, Gao J, Siewert B, Wielopolski P, Edelman RR. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurology. (1995) 37:231–41. doi: 10.1002/ana.410370214

31. Tong DC, Yenari MA, Albers GW. O'Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke. Neurology. (1998) 50:864–9. doi: 10.1212/WNL.50.4.864

32. Löblöd KO, Laubach HJ, Baird AE, Curtin F, Schlaug G, Edelman RR, et al. Clinical experience with diffusion-weighted MR in patients with acute stroke. AJNR Am J Neuroradiol. (1999) 19:1061–6.

33. Grant PE, He I, Halpern EF, Wu O, Schaefer PW, Schwamm LH, et al. Frequency and clinical context of decreased apparent diffusion coefficient reversal in the human brain. Radiology. (2001) 221:43–50. doi: 10.1148/radiol.2211001523

34. Muir KW, Buchan A, von Kummer R et al. Imaging of acute stroke. Lancet. (2006) 5:755–68. doi: 10.1016/S1474-4422(06)70545-2

35. Yu D, Gonzalez RG, Schaefer P. Conventional MRI and MR angiography of stroke. In: Gonzalez RG, Hirsch J, Koroshetz W, et al, editors. Acute Ischemic Stroke: Imaging and Intervention. Berlin: Springer-Verlag (2006). p. 115–35.

36. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia—the ischemic penumbra. Stroke. (1981) 12:723–5. doi: 10.1161/01.STR.12.6.723

37. Yu W, Liu L. Therapeutic Window Beyond Cerebral Ischemic Reperfusion Injury. In: Jiang W, Yu W, Yu Y, Shi Z, Luo B, Zhang J, editors. Cerebral Ischemic Reperfusion Injuries (CIRI). Springer Series in Translational Stroke Research. Cham: Springer Nature (2018). p. 245–59.
Kucinski T, Naumann D, Knab R, Schoder V, Wegener S, Fiehler J, et al. Tissue perfusion CT of the brain: diagnostic approach for early detection of ischemic stroke. *Radiology*. (1998) 209:85–93. doi: 10.1148/radiology.209.1.9760817

Koenig M, Kraus M, Theek C, Klotz E, Gahlen W, Heuser L. Quantitative assessment of the ischemic brain by means of perfusion-related parametric mapping derived from perfusion CT. *Stroke*. (2001) 32:431–7. doi: 10.1161/01.STR.32.2.431

Wintemberg M, Reichhart M, Thiran JP, Maeder P, Chalaron M, Schnyder P, et al. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. *Ann Neurol*. (2002) 51:417–32. doi: 10.1002/ana.10136

Schramm P, Schellinger PD, Klotz E, Kallenberg K, Fiebach JB, Kilkenyi S, et al. Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours’ duration. *Stroke*. (2004) 35:1652–58. doi: 10.1161/01.STR.0000131271.54098.22

Murphy BD, Fox AJ, Lee DH, Sahlas DJ, Black SE, Hogan MJ, et al. Identification of penumbra and infarct in acute ischemic stroke using computed tomography perfusion-derived blood flow and blood volume. *Stroke*. (2006) 37:1771–7. doi: 10.1161/01.STR.000022743.96808.33

Turk A, Magarik JA, Chaudry I, Turner RD, Nicholas J, Holmstedt CA, et al. CT perfusion-guided patient selection for endovascular treatment of acute ischemic stroke is safe and effective. *J NeuroInterv Surg* (2012) 4:26–5. doi: 10.1136/neurint-surg-2011-010067

Bouslama M, Haussen DC, Grossberg JA, Reinhart K, Kiefbach JB, et al. Predicted potential responders. *Eur J Neurol*. (2018) 25:1093–9. doi: 10.1111/ene.13660

Yu and Jiang A Simple Imaging Guide for Thrombectomy under the testing for understanding stroke evolution (DEFUSE) study. *Frontiers in Neurology* | www.frontiersin.org May 2019 Volume 10 Article 502

Gautheron V, Xie Y, Tisserand M, Roault H, Soize S, Naggaro O, et al. Outcome after reperfusion therapy with large baseline diffusion-weighted imaging stroke lesions: A THAIRE Trial (Mechanical Thrombectomy After Intravenous alteplase versus alteplase alone after stroke) subgroup analysis. *Stroke*. (2018) 49:750–3. doi: 10.1161/STROKEAHA.117.022044

Manceau PF, Soize S, Gawlitza M, Fabre G, Bakchine S, Duriot C. Is there a benefit of mechanical thrombectomy in patients with large stroke (DWI-ASPECTS ≤ 5)? *Eur J Neurol*. (2018) 25:105–10. doi: 10.1111/ene.13460

Desai SM, Haussen DC, Aghaebrahim A, Al-Bayati AR, Santos R, Nogueira RG, et al. Thrombectomy 24 hours after stroke: beyond DAWN. *J NeuroInterventional Surg*. (2018) 10:139–42. doi: 10.1136/neurintsurg-2018-013923

Ramadan NM, Khatri P, McKinney AM, Swenson B, et al: Blood- brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. *Neurology*. (2012) 79 (suppl 1):S52–7. doi: 10.1212/WNL.0b013e3182697e70

Singer OC, Humphich MC, Fiehler J, Albers GW, Lansberg MG, Kastrup A, et al. Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. *Ann Neurol*. (2008) 63:52–60. doi: 10.1002/ana.21222

Campbell BC, Christensen S, Parsons MW, Churilov L, Desmond PM, Barber PA, et al. Advanced imaging improves prediction of hemorrhage after stroke thrombolysis. *Ann NeuroL*. (2013) 73:510–9. doi: 10.1002/ana.23837

Abou-Chedl A, Reginelli J, Bajzer CT, Yadav JS. Intensive treatment of hypertension decreases the risk of hyperperfusion and intracerebral hemorrhage following carotid artery stenting. *Catheter Cardiovasc Interv*. (2007) 69:690–6. doi: 10.1002/ccd.20693

Geussens RR, Borst J, Lucas M, Boers AM, Berkhemer OA, Roos YB, et al. MR CLEAN Trial Investigators. Characteristics of misclassified CT perfusion ischemic core in patients with acute ischemic stroke. *PLoS ONE*. (2015) 10:0141571. doi: 10.1371/journal.pone.0141571

Saver JL, Goyal M, van der Luit A, Menon BK, Majoie CB, Dippel DW, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. *JAMA*. (2016) 316:1279–88. doi: 10.1001/jama.2016.12266

Campbell BC, Majoie CBLM, Albers GW, Menon BK, Yassi N, Sharma G et al. for the HERMES collaborators. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. *Lancet Neurol*. (2019) 18:46–55. doi: 10.1016/S1474-4422(18)30314-4

Sheth KN, Terry JR, Nogueira RG, Horev A, Nguyen TN, Fong AK, et al. Advanced modality imaging evaluation in acute stroke may lead to delayed endovascular reperfusion therapy without improvement in clinical outcomes. *J NeuroInterv Surg* (2013) 5(suppl 1): i62–i65. doi: 10.1136/neurintsurg-2012-010512

Adams HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. *Neurology*. (1999) 53:126–31. doi: 10.1212/wnl.53.1.126

Sheth KN, Terry JR, Nogueira RG, Horev A, Nguyen TN, Fong AK, et al. Advanced modality imaging evaluation in acute stroke may lead to delayed endovascular reperfusion therapy without improvement in clinical outcomes. *J NeuroInterv Surg* (2013) 5(suppl 1): i62–i65. doi: 10.1136/neurintsurg-2012-010512

Adams HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale score strongly predicts outcome after mechanical thrombectomy. *Neurology*. (2001) 57:1205–11. doi: 10.1212/wnl.57.7.1205

Rebelo LC, Bouslama M, Haussen DC, Dehkharghani S, Grossberg JA, Belagaje S, et al. Endovascular treatment for patients with acute stroke who have a large ischemic core and large mismatch imaging profile. *JAMA Neurol*. (2017) 74:34–40. doi: 10.1001/jamaneurol.2016.3954

Ducroux C, Khoury N, Lecler A, Blanc R, Chetrit A, Redjem H. Application of the DAWN clinical imaging mismatch and DEFUSE 3 selection criteria: benefit seems similar but restrictive volume cut-offs might omit potential responders. *Eur J Neurol*. (2018) 25:1093–9. doi: 10.1111/ene.13660
Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2018) 49:e46–110. doi: 10.1161/STR.0000000000000172

92. Santos T, Carvalho A, Cunha AA, Rodrigues M, Gregório T, Paredes I, et al. NCCT and CTA-based imaging protocol for endovascular treatment selection in late presenting or wake-up strokes. J NeuroInterventional Surg. (2019) 11:200–3. doi: 10.1136/neurintsurg-2018-014051

93. McTaggart RA, Jovin TG, Lansberg MG, Mlynash M, Jayaraman MV, Choudhri OA, et al. Alberta stroke program early computed tomographic scoring performance in a series of patients undergoing computed tomography and MRE: reader agreement, modality agreement, and outcome prediction. Stroke. (2015) 46:407–412. doi: 10.1161/STROKEAHA.114.006564

Conflict of Interest Statement: WY is a scientific consultant at Stryker Neurovascular.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Yu and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.